James Rubenstein, PhD, MD

Hematologist

Dr. James Rubenstein is a hematologist-oncologist or blood disorders specialist, whose expertise is treating patients with neurologic complications from cancer, in particular patients with non-Hodgkin's lymphoma involving the brain, called central nervous system (CNS) lymphoma. He also specializes in patients with cancer that has spread to the brain from other parts of the body. In his research, he is interested in immunologic tools to improve tumor response to chemotherapy and radiation treatment, to minimize toxicity from treatment and the development of tumor biomarkers to diagnose brain tumors.

Rubenstein earned a medical degree at Cornell University Medical College in New York and completed a residency in internal medicine at Stanford University Medical Center. He earned a Ph.D. in molecular and cellular neurosciences at Rockefeller University in New York and completed a fellowship in hematology and oncology at UCSF, including training in neuro-oncology. He is a member of the American Society of Hematology, American Society of Clinical Oncology and American Association of Cancer Research. He won a Scholar in Clinical Research Award from the Leukemia and Lymphoma Society and a Research Career Award from the National Cancer Institute. He is a professor of medicine at UCSF.

Clinics

Hematology and Blood and Marrow Transplant
400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051
Fax: (415) 353-2467

Hours: Monday to Friday, 8 a.m. - 5 p.m

Conditions & Treatments

Board Certification

Medical Oncology, American Board of Internal Medicine

Academic Title

Professor

More about James Rubenstein

Additional Languages

French

Education

Cornell University Medical College 1992

Residencies

Stanford, Internal Medicine 1995

Fellowships

UCSF Cancer Research Institute, Hematology/Oncology 1997

Selected Research and Publications

  1. Rubenstein JL. Biology of CNS lymphoma and the potential of novel agents. Hematology Am Soc Hematol Educ Program. 2017 Dec 08; 2017(1):556-564.
  2. Bever GJ, Kim DJ, Afshar AR, Rubenstein JL, Damato BE. THERAPEUTIC VITRECTOMY AS AN ADJUNCT TREATMENT TO SYSTEMIC CHEMOTHERAPY FOR INTRAOCULAR LYMPHOMA. Retin Cases Brief Rep. 2017 Nov 23.
  3. Gupta NK, Wang CC, Mannis GN, Yu JJ, Rubenstein JL. Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy. Leuk Lymphoma. 2017 Nov; 58(11):2748-2751.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.